Drugs in MeSH Category Fatty Acid Synthesis Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	ISONIAZID	isoniazid	TABLET;ORAL	080522-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Hikma Intl Pharms	ISONIAZID	isoniazid	TABLET;ORAL	080212-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Everylife	STANOZIDE	isoniazid	TABLET;ORAL	080126-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	ISONIAZID	isoniazid	TABLET;ORAL	085790-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Epic Pharma Llc	ISONIAZID	isoniazid	TABLET;ORAL	008678-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Fatty Acid Synthesis Inhibitors

Last updated: January 13, 2026

---

Executive Summary

The therapeutic class of Fatty Acid Synthesis Inhibitors has garnered significant attention due to its potential in managing metabolic disorders, certain cancers, and infectious diseases. This analysis provides a comprehensive overview of the current market landscape and patent activity, emphasizing key innovations, leading players, drug development trends, and intellectual property strategies.

Market drivers include the rising prevalence of metabolic syndromes (e.g., obesity, type 2 diabetes), increasing cancer incidences, and the pursuit of targeted therapies. Patent activity indicates a focus on novel inhibitors with improved specificity, bioavailability, and safety profiles, predominantly in early to late clinical phases. The analysis underscores the importance of ongoing innovation to maintain competitive advantage amid patent expirations and emerging biosimilar competition.

---

1. What are Fatty Acid Synthesis Inhibitors?

Definition:
Fatty acid synthesis inhibitors target enzymes central to lipogenesis, primarily Fatty Acid Synthase (FASN), a multifunctional enzyme catalyzing de novo fatty acid production. Overexpression of FASN is linked to tumor growth, metabolic disorders, and pathogenic infections, making it a therapeutic target.

Target Enzymes and Pathways:

Enzyme	Role	Therapeutic Potential	Examples
FASN (Fatty Acid Synthase)	Catalyzes synthesis of palmitate	Cancer, obesity, infection	TVB-2640, GDC-0660
ACC (Acetyl-CoA Carboxylase)	Converts acetyl-CoA to malonyl-CoA	Metabolic disorders	NDGA, PF-05175157
ACLY (ATP Citrate Lyase)	Links citrate to acetyl-CoA production	Cancer, metabolic syndromes	SB-611075

Clinical Relevance:

• Oncology: Suppresses tumor proliferation by inhibiting lipogenesis required for membrane synthesis.
• Metabolic Diseases: Reduces lipogenesis, impacting obesity and diabetes.
• Infections: Limiting fatty acid synthesis impairs pathogen replication.

---

2. Market Overview and Key Players

Global Market Size:

Year	Market Value (USD billion)	Expected CAGR (2022-2027)	Sources
2022	$1.2	8.1%	MarketsandMarkets[1]
2027	$2.2

Leading Companies:

Company	Focus Area	Notable Drugs	R&D Focus	Patents (Number)
Novartis	Oncology, Metabolic Disorders	TVB-2640 (FASN inhibitor)	FASN, ACC inhibitors	50+
Gilead Sciences	Oncology	GS-0976 (FASN inhibitor)	FASN, metabolic pathways	30+
Pfizer	Oncology	PF-05175157 (ACC inhibitor)	Lipogenesis, cancer	20+
Merck	Various	Multiple early pipeline compounds	Enzyme inhibition	15+

Notable Drugs in Development:

Drug	Developer	Indication	Phase	Mechanism	Patent Families
TVB-2640	Novartis	Solid tumors, NSCLC	Phase 2	FASN inhibitor	10+
GDC-0660	Genentech (Roche)	Oncology	Preclinical	FASN inhibitor	8
GS-0976	Gilead	NASH (Non-Alcoholic Steatohepatitis)	Phase 2	FASN inhibitor	12

---

3. Patent Landscape Analysis

Patent Filing Trends (2012–2022):

Year	Number of Patents Filed	Major Applicants	Focus Areas	Trends
2012–2015	45	Novartis, Gilead	FASN inhibitors	Growing interest in cancer targets
2016–2018	60	Multiple, including biotech startups	Combination therapies	Shift towards synergistic approaches
2019–2022	85	Major pharma, universities	Selectivity, bioavailability	Emphasis on patent quality and formulation

Patent Focus Areas:

1. Chemical Entities: Novel small molecule inhibitors of FASN, ACC, ACLY.
2. Method of Use: Methods for treating cancers, metabolic syndromes.
3. Drug Delivery: Formulations enhancing targeting and reducing toxicity.
4. Biomarker-Linked Patents: Diagnostics to identify patient subgroups responsive to fatty acid synthesis inhibition.

Key Patent Holders:

Patent Holder	Number of Patents	Notable Patents	Focus Area
Novartis	50+	FASN inhibitors with improved selectivity	Composition, use
Gilead	30+	NASH-focused molecules	Therapeutic indications
Pfizer	20+	ACC inhibitors	Metabolic pathway modulation
University of Texas	15	Novel synthesis methods	Chemical innovations

Patent Strategies:

• Polyphasic Protection: Filing composition, method, and formulation patents.
• Filing in Emerging Markets: Expanding patent rights across Asia and Latin America.
• Evergreening: Incremental modifications to extend patent life or circumvent generic entry.

---

4. Competitive Advantages and Innovation Trends

Differentiation Strategies:

Strategy	Focus	Examples
Selectivity	Minimize off-target effects	TVB-2640 selective for tumor FASN
Combination Therapy	Use with chemotherapeutics	TVB-2640 + chemotherapy
Formulation Enhancement	Improve bioavailability	Liposomal or nano-formulations
Biomarker Development	Precision medicine	Elevated FASN expression as biomarker

R&D Trends:

• Increasing focus on dual-target inhibitors (FASN + ACC).
• Emphasis on biomarker-guided trials.
• Exploration of targeted delivery systems (nanoparticles, liposomes).
• Inclusion of non-invasive diagnostics linked with patent portfolios.

---

5. Regulatory and Policy Environment

Regulatory Pathways:

Region	Agency	Approval Process	Key Considerations
U.S.	FDA	NDA/ANDA, Breakthrough Designation	Safety, efficacy, orphan status
EU	EMA	Centralized Procedure	Risk-benefit analysis
China	NMPA	Marketing Authorization	Fast track for unmet needs

Patent Policy Impact:

• Patent term extensions under patent law (e.g., US Patent Term Restoration Act).
• Data exclusivity periods impacting market entry.
• Patent linkage systems affecting generic approval.

---

6. Comparative Analysis: Fatty Acid Synthesis Inhibitors vs Other Lipogenesis Inhibitors

Aspect	FASN Inhibitors	ACC Inhibitors	ACLY Inhibitors
Target Enzyme	Fatty Acid Synthase	Acetyl-CoA Carboxylase	ATP Citrate Lyase
Clinical Stage	Phase 2 Focus	Early Phase	Preclinical
Market Focus	Oncology, NASH	Metabolic Syndrome	Oncology

Implication: FASN inhibitors currently dominate pipeline activity, driven by tumor dependency on lipogenesis.

---

7. Future Outlook and Challenges

Outlook Aspect	Opportunity	Challenge	Sources
Innovation	Highly selective, multi-target agents	Off-target toxicity	[2]
Market Expansion	Personalized therapies	Regulatory hurdles	[3]
Patent Landscape	Expansion in emerging markets	Patent cliff, generic entry	[4]

Key Challenges Include:

• Managing toxicity and side effects.
• Demonstrating clinical efficacy in diverse populations.
• Overcoming patent expirations with next-generation molecules.

---

Key Takeaways

• The fatty acid synthesis inhibitor class is evolving, with promising candidates targeting FASN, ACC, and ACLY, especially in oncology and metabolic disorders.
• Market growth is robust, projected to nearly double by 2027, driven by pipeline activity and unmet medical needs.
• Patent activity underscores a focus on selectivity, combination therapies, and innovative delivery systems, with Novartis and Gilead leading.
• High R&D costs, regulatory hurdles, and patent expirations pose challenges; strategic patent filings and continuous innovation are critical.
• Personalized medicine approaches and biomarker-guided therapies will likely reshape the competitive landscape.

---

FAQs

Q1: What is the most advanced fatty acid synthesis inhibitor currently in clinical trials?
A1: TVB-2640 (Novartis) is the most advanced, currently in Phase 2 trials for solid tumors and non-small cell lung cancer (NSCLC).

Q2: Which diseases are the primary targets for fatty acid synthesis inhibitors?
A2: The main indications include oncology (various solid tumors and hematological cancers), NASH, and metabolic syndromes like obesity and type 2 diabetes.

Q3: What are the main patent strategies used by pharmaceutical companies in this class?
A3: Strategies include filing for composition of matter patents, method of use patents, formulations innovations, and filing in emerging markets to extend commercial exclusivity.

Q4: How do fatty acid synthesis inhibitors compare with other metabolic pathway inhibitors?
A4: They tend to be highly focused on cancer targets like FASN, with recent efforts to extend into metabolic diseases. Their specificity and the evolving patent landscape differentiate them from broader metabolic pathway inhibitors.

Q5: What are the key challenges faced in bringing fatty acid synthesis inhibitors to market?
A5: Challenges include managing toxicity profiles, demonstrating clear clinical efficacy, navigating regulatory approvals, and patent cliffs leading to generic competition.

---

References

[1] MarketsandMarkets, "Fatty Acid Synthesis Inhibitors Market – Global Forecast," 2021.
[2] Zhang et al., "Challenges and prospects of targeting fatty acid synthesis in cancer," Nature Reviews Drug Discovery, 2020.
[3] U.S. FDA Guidance, "Patent Term Restoration and Extensions," 2022.
[4] European Patent Office, "Patent Strategies in Biotech," 2021.

---

For business professionals, understanding the nuanced landscape of fatty acid synthesis inhibitors offers strategic insights into patent planning, R&D investment, and market entry considerations.